The wait wasn't pretty, but the final result was. Yesterday, the Food and Drug Administration approved Novo Nordisk's
Better late than never? Maybe not.
Victoza is in the same class as Amylin Pharmaceuticals'
Needless to say, Novo Nordisk is trying its best to hit the ground running with a launch within weeks, but that may not be enough. Doctors who know that once-weekly Byetta could be just a few months off probably will be less likely to switch patients from twice-daily Byetta to once-daily Victoza now.
Even if once-weekly Byetta gets delayed, Novo Nordisk may have trouble getting new patients onto Victoza. The label says the drug shouldn't be used as a first line treatment, probably because of the thyroid cancer seen in studies done in rats. Twice-daily Byetta, on the other hand, is approved as a first-line treatment. While I'm not convinced that many doctors would prescribe Byetta before trying oral medications developed by Merck
At this point, Novo Nordisk's best chance at a victory for Victoza is if once-weekly Byetta gets hung up at the FDA. Or better yet, hung out to dry.
Timing is everything. Except when it's not, says Rex Moore.
Novo Nordisk is a Motley Fool Global Gains selection. Investing internationally doesn't have to be scary, and it can certainly be profitable. See all our current picks for great global investments with a free 30-day trial.
More from The Motley Fool
Novo Nordisk A/S Slogs Through the Year
It was another lackluster quarter from the diabetes specialist.
The 3 Best Diabetes Stocks to Buy in 2018
Not all diabetes stocks are created equally.
Here's Why Novo Nordisk A/S Gained 12% in August
Last summer, the diabetes-focused pharmaceutical issued distressing guidance due to pricing pressure worries, but the forecast troubles failed to arrive.